PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial.
Lordick F, Ott K, Krause BJ, Weber WA, Becker K, Stein HJ, Lorenzen S, Schuster T, Wieder H, Herrmann K, Bredenkamp R, Höfler H, Fink U, Peschel C, Schwaiger M, Siewert JR.
Lordick F, et al. Among authors: herrmann k.
Lancet Oncol. 2007 Sep;8(9):797-805. doi: 10.1016/S1470-2045(07)70244-9.
Lancet Oncol. 2007.
PMID: 17693134
Clinical Trial.